Edwards Lifesciences Corp. said its 4Q16 revenue will come in at the low end of its $750 million to $790 million guidance range, but strong developments in the company's product pipeline will give it a solid foundation long term. During its annual analyst day, the Irvine, Calif.-based company emphasized that the transcatheter aortic valve replacement (TAVR) market would be at the heart of its plans for the coming year. Analysts seemed to walk away from the event with a highly favorable perspective of the company's general direction. Read More
